21 September 2022, 7:30 CEST – Taipei City, Taiwan and Liege, Belgium – Lotus Pharmaceutical Co., Ltd. (TWSE: 1795, “Lotus”) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA, “Mithra”) today are pleased to announce that Estelle®, the first-of-its-kind oral contraceptive with a novel estrogen developed by Mithra, has been approved by both Taiwan Food and Drug Administration (TFDA) and Hong Kong Drug Office, Department of Health, under the trademark ALYSSA®. Through this partnership with Mithra, Lotus will be exclusively marketing the product in Taiwan and Hong Kong.
https://www.mithra.com/wp-content/uploads/2022/09/MicrosoftTeams-image-133.jpg 1080 1920 Célia Berlemont https://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.png Célia Berlemont2022-09-21 07:30:412022-09-20 17:09:00Mithra and Lotus announce approval of ALYSSA®, an innovative oral contraceptive, in both Taiwan and Hong Kong
Rue Saint-Georges 5
Tel. : +32 (0)4 349 28 22
Fax : +32 (0)4 349 28 21
Email : firstname.lastname@example.org